A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10)

Ann Hematol. 2003 Nov;82(11):716-20. doi: 10.1007/s00277-003-0728-8. Epub 2003 Aug 28.

Authors

B Wassmann¹, N Gökbuget, U J Scheuring, A Binckebanck, R Reutzel, H Gschaidmeier, D Hoelzer, O G Ottmann; GMALL Study Group

Affiliation

¹ Department of Hematology and Oncology, Medizinische Klinik III, Johann Wolfgang Goethe Universität, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.

PMID: 14648032
DOI: 10.1007/s00277-003-0728-8

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase II
Comparative Study
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Benzamides
Drug Administration Schedule
Female
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Male
Middle Aged
Neoplasm, Residual / diagnosis
Piperazines / therapeutic use*
Pyrimidines / therapeutic use*
Remission Induction / methods

Substances

Benzamides
Piperazines
Pyrimidines
Imatinib Mesylate